Fortekor Tablet - 5mg (Palatable) For Dogs Only are divisible, palatable tablets for oral use, formulated to treat heart failure in dogs. Each tablet contains an active ingredient called Benazepril which is rapidly absorbed after ingestion. Fortekor lowers the blood pressure and volume loading on the heart and can significantly increase the life span of dogs with heart failure. It also reduces other medical issues, such as coughing, and improves your dog’s quality of life. Fortekor is easily excreted by dogs through both the urinary and biliary routes and is not affected by in dogs with impaired renal functions, so no adjustment to dosage is necessary.
FORTEKOR Flavour should be given orally once daily, with or without food. The duration of treatment is unlimited. FORTE- KOR Flavour 5 mg tablets are flavoured and are taken voluntarily by most dogs and cats.
Dogs: Fortekor should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5) benazepril hydrochloride / kg bodyweight once daily, according to the following table:Weight of Dog (kg) Standard dose Double dose >5-10 0.5 tablet 1 tablet >10-20 1 tablet 2 tablets
The dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon. FORTEKOR Flavour has been given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary products without demonstrable adverse interactions.
You should carefully read all product packaging and labels prior to use.
Do not store above 25?C.
Each time an unused half tablet is stored, it should be returned to the open blister space, inserted back into the cardboard box and kept in a safe place out of the reach and sight of children. Tablet halves should be used within 2 days.
Do not use during pregnancy or lactation. The safety of FORTEKOR has not been established in breeding, pregnant or lactating dogs and cats. Benazepril reduced ovary/oviduct weights in cats when administered daily at 10 mg/kg body weight for 52 weeks.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.
Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.
The efficacy and safety of FORTEKOR has not been established in dogs and cats below 2.5 kg body weight.
For animal treatment only. For oral use only. Wash hands after use. In case of accidental oral ingestion, seek medical advice immediately and show the label or the package leaflet to the physician. Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.
In double-blind clinical trials in dogs with congestive heart failure, FORTEKOR was well tolerated with an incidence of adverse reactions lower than observed in placebo-treated dogs. No evidence of renal toxicity of the veterinary medicinal product has been observed (in dogs or cats) during clinical trials. However, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts during therapy.
A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue.
In cats and dogs with chronic kidney disease, FORTEKOR may increase plasma creatinine concentrations at the start of therapy. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.
FORTEKOR may increase food consumption and body weight in cats. Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in rare occasions in cats.
In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of FORTEKOR and other anti-hypertensive agents (e.g. calcium channel blockers, beta-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other medications with a hypotensive effect should be considered with care. Renal function and signs of hypotension (lethargy, weakness etc.) should be monitored closely and treated as necessary.
Interactions with potassium preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using FORTEKOR in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.